Korea Pharma has signed a contract to supply Accrufer

Overcoming side effects of existing PO formulations and relieving inconvenience of injections

Korea's only U.S. licensed anemia drug, IBD, and CKD are expanded

Korea Pharma announced on Monday that it has signed an exclusive contract with Shield Theapeutics to supply the anaemic drug Accrufer in Korea.

 

Anemia is very common in patients with inflammatory bowel disease (IBD) and chronic kidney disease (CKD).

 

Poor treatment of anemia increases the morbidity and morbidity of cardiovascular disease.

 

According to Korea Pharma, existing oral anemia treatments have severe side effects such as gastrointestinal disorders and constipation.

 

Since intravenous iron tablets require visiting hospitals once to three times a week, it takes time and is economically burdensome.

 

Accrufer is an ideal alternative because it does not cause side effects such as gastrointestinal disorders and constipation, and absorbs as much iron as the body needs.

 

Accrufer is a formulation that can replace the main used iron in the AEGIS-H2H study published in March 2019.

 

Accrufer is expected to reduce the economic burden of intravenous iron preparations and improve patient conformity.

 

Accrufer is approved by the FDA and EMA and is sold in Europe and the United States.

 

It is the only oral anemia treatment in Korea that has been recognized for its excellent efficacy and safety with FDA approval.

 

"Korea Pharma is a successful pharmaceutical company with outstanding performance in product development and commercial success," CEO Greg Madison said.

 

"Iron deficiency is a global problem, and through this agreement, more iron deficiency patients in Korea will be able to use Accrufer in the near future," he said.

 

Park Eun-hee, CEO of Korea Pharma, expects that the company will be able to provide iron deficiency treatment to Korea through Accrufer.

 

Korea Pharma signed the world's first one-liter PEG bowel cleansing Plenvu exclusive contract with Norgine in December 2018, and this time it has expanded to IBD and CKD through Accrufer exclusive contract.